Comera Life Sciences Holdings, Inc.

2023 Q4 Form 10-Q Financial Statement

#000095017023062130 Filed on November 09, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3 2022 Q3

Balance Sheet

Concept 2023 Q4 2023 Q3 2022 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $1.768M $2.669M
YoY Change -33.77% 492.45%
Cash & Equivalents $1.768M $2.700M
Short-Term Investments
Other Short-Term Assets $762.6K $1.326M
YoY Change -42.48% 840.98%
Inventory
Prepaid Expenses
Receivables $100.0K $293.8K
Other Receivables $0.00 $0.00
Total Short-Term Assets $2.630M $4.289M
YoY Change -38.67% 625.15%
LONG-TERM ASSETS
Property, Plant & Equipment $186.7K $192.6K
YoY Change -3.04%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $93.20K $93.20K
YoY Change 0.0%
Total Long-Term Assets $441.5K $648.2K
YoY Change -31.89% -99.39%
TOTAL ASSETS
Total Short-Term Assets $2.630M $4.289M
Total Long-Term Assets $441.5K $648.2K
Total Assets $3.072M $4.937M
YoY Change -37.78% -95.41%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.145M $1.437M
YoY Change -20.32%
Accrued Expenses $1.205M $887.0K
YoY Change 35.81% 60240.95%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $389.9K $911.1K
YoY Change -57.21%
Total Short-Term Liabilities $2.932M $3.430M
YoY Change -14.51% 233238.84%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $37.27K $503.2K
YoY Change -92.59% -94.58%
Total Long-Term Liabilities $37.27K $503.2K
YoY Change -92.59% -94.58%
TOTAL LIABILITIES
Total Short-Term Liabilities $2.932M $3.430M
Total Long-Term Liabilities $37.27K $503.2K
Total Liabilities $2.970M $3.933M
YoY Change -24.5% -57.64%
SHAREHOLDERS EQUITY
Retained Earnings -$41.00M -$31.90M
YoY Change 28.53%
Common Stock $36.73M $28.51M
YoY Change 28.82%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$4.221M -$3.428M
YoY Change
Total Liabilities & Shareholders Equity $3.072M $4.937M
YoY Change -37.78% -95.41%

Cashflow Statement

Concept 2023 Q4 2023 Q3 2022 Q3

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Central Index Key
EntityCentralIndexKey
0001907685
dei Amendment Flag
AmendmentFlag
false
CY2023Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
1-41403
dei Entity Registrant Name
EntityRegistrantName
Comera Life Sciences Holdings, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
87-4706968
dei Entity Address Address Line1
EntityAddressAddressLine1
12 Gill Street
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 4650
dei Entity Address City Or Town
EntityAddressCityOrTown
Woburn
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
01801
dei City Area Code
CityAreaCode
617
dei Local Phone Number
LocalPhoneNumber
871-2101
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
30737796
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1767870
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
446607
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
28655164
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-40950566
CY2022Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
1505625
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
34320
CY2022Q4 us-gaap Deferred Costs Current
DeferredCostsCurrent
90047
CY2023Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
862626
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
986499
CY2023Q3 us-gaap Assets Current
AssetsCurrent
2630496
CY2022Q4 us-gaap Assets Current
AssetsCurrent
3063098
CY2023Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
50000
CY2022Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
50000
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
186738
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
257186
CY2023Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
161515
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
313629
CY2023Q3 us-gaap Security Deposit
SecurityDeposit
43200
CY2022Q4 us-gaap Security Deposit
SecurityDeposit
43200
CY2023Q3 us-gaap Assets
Assets
3071949
CY2022Q4 us-gaap Assets
Assets
3727113
CY2023Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
1144822
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1458267
CY2023Q3 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
1226129
CY2022Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
1295764
CY2023Q3 us-gaap Long Term Debt Current
LongTermDebtCurrent
389872
CY2022Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
455562
CY2022Q4 cmra Deposit Liabilities Current
DepositLiabilitiesCurrent
1505625
CY2022Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
144280
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
171596
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
199184
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
2932419
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
5058682
CY2023Q3 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
37266
CY2022Q4 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
277507
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
120302
CY2023Q3 us-gaap Liabilities
Liabilities
2969685
CY2022Q4 us-gaap Liabilities
Liabilities
5456491
CY2023Q3 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
1000000
CY2022Q4 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
1000000
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
30737796
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
30737796
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
16709221
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
16709221
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
2759
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
1671
CY2023Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
36727205
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-34903923
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-4220602
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-6247088
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
3071949
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
3727113
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
136310
CY2022Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
234922
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
844280
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
476982
CY2023Q3 us-gaap Cost Of Revenue
CostOfRevenue
41961
CY2022Q3 us-gaap Cost Of Revenue
CostOfRevenue
60963
us-gaap Cost Of Revenue
CostOfRevenue
214520
us-gaap Cost Of Revenue
CostOfRevenue
160030
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
366015
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
394800
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
945415
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1250570
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1885405
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2314554
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5822107
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8027316
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
2251420
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
2709354
us-gaap Operating Expenses
OperatingExpenses
6767522
us-gaap Operating Expenses
OperatingExpenses
9277886
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-2157071
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-2535395
us-gaap Operating Income Loss
OperatingIncomeLoss
-6137762
us-gaap Operating Income Loss
OperatingIncomeLoss
-8960934
CY2023Q3 cmra Change In Fair Value Of Derivative Warrant Liabilities
ChangeInFairValueOfDerivativeWarrantLiabilities
9325
CY2022Q3 cmra Change In Fair Value Of Derivative Warrant Liabilities
ChangeInFairValueOfDerivativeWarrantLiabilities
500327
cmra Change In Fair Value Of Derivative Warrant Liabilities
ChangeInFairValueOfDerivativeWarrantLiabilities
108678
cmra Change In Fair Value Of Derivative Warrant Liabilities
ChangeInFairValueOfDerivativeWarrantLiabilities
1954767
cmra Reverse Recapitalization Issuance Costs In Excess Of Gross Proceeds
ReverseRecapitalizationIssuanceCostsInExcessOfGrossProceeds
6566821
CY2022Q3 cmra Common Stock Purchase Agreement Issuance Costs
CommonStockPurchaseAgreementIssuanceCosts
1029077
cmra Common Stock Purchase Agreement Issuance Costs
CommonStockPurchaseAgreementIssuanceCosts
1029077
CY2023Q3 us-gaap Interest Expense
InterestExpense
5965
CY2022Q3 us-gaap Interest Expense
InterestExpense
12696
us-gaap Interest Expense
InterestExpense
17559
us-gaap Interest Expense
InterestExpense
12773
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-426666
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
3360
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-541446
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
91119
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-6080570
CY2023Q3 us-gaap Profit Loss
ProfitLoss
-2153711
CY2022Q3 us-gaap Profit Loss
ProfitLoss
-3076841
us-gaap Profit Loss
ProfitLoss
-6046643
us-gaap Profit Loss
ProfitLoss
-15041504
CY2023Q3 cmra Accretion Of Convertible Preferred Stock To Redemption Value
AccretionOfConvertiblePreferredStockToRedemptionValue
85468
CY2022Q3 cmra Accretion Of Convertible Preferred Stock To Redemption Value
AccretionOfConvertiblePreferredStockToRedemptionValue
86816
cmra Accretion Of Convertible Preferred Stock To Redemption Value
AccretionOfConvertiblePreferredStockToRedemptionValue
258156
cmra Accretion Of Convertible Preferred Stock To Redemption Value
AccretionOfConvertiblePreferredStockToRedemptionValue
287984
CY2023Q3 cmra Net Loss Attributable To Common Stockholders
NetLossAttributableToCommonStockholders
-2239179
CY2022Q3 cmra Net Loss Attributable To Common Stockholders
NetLossAttributableToCommonStockholders
-3163657
cmra Net Loss Attributable To Common Stockholders
NetLossAttributableToCommonStockholders
-6304799
cmra Net Loss Attributable To Common Stockholders
NetLossAttributableToCommonStockholders
-15329488
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.1
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.1
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.2
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.2
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.31
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.31
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.85
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.85
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
23113051
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
23113051
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
16024011
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
16024011
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
20448666
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
20448666
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8294938
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8294938
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-6247088
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Increase In Carrying Amount Of Redeemable Preferred Stock
AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock
86816
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
300765
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-2481312
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-5264844
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Increase In Carrying Amount Of Redeemable Preferred Stock
AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock
85872
CY2023Q2 cmra Conversion Of Private Warrants To Public Warrants
ConversionOfPrivateWarrantsToPublicWarrants
131562
CY2023Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1443
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
278969
CY2023Q2 us-gaap Profit Loss
ProfitLoss
-1411620
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-6350362
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Increase In Carrying Amount Of Redeemable Preferred Stock
AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock
85468
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
267560
CY2023Q3 us-gaap Profit Loss
ProfitLoss
-2153711
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-4220602
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-14686247
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
429430
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
42556
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-2879395
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
-17093656
CY2022Q2 cmra Issuance Of Common Stock Upon Exercise Of Stock Options Net Of Shares Withheld To Settle Tax Withholding Requirements
IssuanceOfCommonStockUponExerciseOfStockOptionsNetOfSharesWithheldToSettleTaxWithholdingRequirements
230071
CY2022Q2 cmra Conversion Of Convertible Preferred Stock Value
ConversionOfConvertiblePreferredStockValue
20857453
CY2022Q2 cmra Share Issuance Costs
ShareIssuanceCosts
7500000
CY2022Q2 cmra Issuance Of Common Stock In Connection With The Transaction And Private Placement Net Of Redemptions Net Tangible Assets And Issuance Costs
IssuanceOfCommonStockInConnectionWithTheTransactionAndPrivatePlacementNetOfRedemptionsNetTangibleAssetsAndIssuanceCosts
3443750
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Increase In Carrying Amount Of Redeemable Preferred Stock
AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock
201168
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
56739
CY2022Q2 us-gaap Profit Loss
ProfitLoss
-9085268
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
-1792079
CY2022Q3 cmra Issuance Of Common Stock Upon Exercise Of Public Warrants Value
IssuanceOfCommonStockUponExerciseOfPublicWarrantsValue
1150
CY2022Q3 cmra Issuance Of Common Stock In Connection With Common Stock Purchase Agreement Value
IssuanceOfCommonStockInConnectionWithCommonStockPurchaseAgreementValue
748888
CY2022Q3 cmra Issuance Of Commitment Shares Value
IssuanceOfCommitmentSharesValue
650000
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Increase In Carrying Amount Of Redeemable Preferred Stock
AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock
86816
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
127690
CY2022Q3 us-gaap Profit Loss
ProfitLoss
-3076841
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
-3428008
us-gaap Profit Loss
ProfitLoss
-6046643
us-gaap Profit Loss
ProfitLoss
-15041504
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
847294
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
226985
us-gaap Depreciation
Depreciation
76098
us-gaap Depreciation
Depreciation
70184
cmra Non Cash Lease Expense
NonCashLeaseExpense
4224
cmra Non Cash Lease Expense
NonCashLeaseExpense
1765
cmra Reverse Recapitalization Issuance Costs In Excess Of Gross Proceeds
ReverseRecapitalizationIssuanceCostsInExcessOfGrossProceeds
6566821
cmra Noncash Common Stock Purchase Agreement Issuance Costs
NoncashCommonStockPurchaseAgreementIssuanceCosts
650000
cmra Change In Fair Value Of Derivative Warrant Liabilities
ChangeInFairValueOfDerivativeWarrantLiabilities
108678
cmra Change In Fair Value Of Derivative Warrant Liabilities
ChangeInFairValueOfDerivativeWarrantLiabilities
1954767
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-34320
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
293821
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-771672
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-460895
us-gaap Increase Decrease In Due From Related Parties
IncreaseDecreaseInDueFromRelatedParties
-286
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-245796
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1019751
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-1510
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
380401
us-gaap Increase Decrease In Security Deposits
IncreaseDecreaseInSecurityDeposits
-11000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-144280
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4813299
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-7924004
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
94009
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
28607
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-94009
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-28607
cmra Proceeds From Vendor Subscription Agreements
ProceedsFromVendorSubscriptionAgreements
288337
cmra Net Proceeds From Transaction And Private Placement
NetProceedsFromTransactionAndPrivatePlacement
3307162
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
49158
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
748888
us-gaap Payments For Repurchase Of Redeemable Convertible Preferred Stock
PaymentsForRepurchaseOfRedeemableConvertiblePreferredStock
453000
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
713489
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
604876
us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
1150
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1443
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
659501
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
4722946
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
4111825
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-184362
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-3840786
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2002232
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
6560140
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1817870
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2719354
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1767870
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2669354
CY2023Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
50000
CY2022Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
50000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1817870
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2719354
cmra Stock Issuance Costs In Accounts Payable And Accrued Expenses And Other Current Liabilities
StockIssuanceCostsInAccountsPayableAndAccruedExpensesAndOtherCurrentLiabilities
110757
cmra Acquisition Of Right Of Use Asset
AcquisitionOfRightOfUseAsset
162634
us-gaap Conversion Of Stock Amount Issued1
ConversionOfStockAmountIssued1
20857453
cmra Financing Of Insurance Premiums
FinancingOfInsurancePremiums
647799
cmra Financing Of Insurance Premiums
FinancingOfInsurancePremiums
1516000
cmra Issuance Of Common Stock To Settle Stock Issuance Costs
IssuanceOfCommonStockToSettleStockIssuanceCosts
3443750
cmra Issuance Of Common Stock In Exchange For Services
IssuanceOfCommonStockInExchangeForServices
68125
cmra Business Combination Issuance Of Series A Preferred Stock To Settle Stock Issuance Costs
BusinessCombinationIssuanceOfSeriesAPreferredStockToSettleStockIssuanceCosts
910000
cmra Accretion On Convertible Preferred Stock
AccretionOnConvertiblePreferredStock
258156
cmra Accretion On Convertible Preferred Stock
AccretionOnConvertiblePreferredStock
287984
cmra Business Combination Issuance Of Series A Preferred Stock To Settle Underwriting Fees Payable Assumed In Transaction
BusinessCombinationIssuanceOfSeriesAPreferredStockToSettleUnderwritingFeesPayableAssumedInTransaction
3395389
cmra Derivative Warrant Liabilities Assumed In Transaction
DerivativeWarrantLiabilitiesAssumedInTransaction
2286379
dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2022-01-25
us-gaap Profit Loss
ProfitLoss
-6000000
us-gaap Profit Loss
ProfitLoss
-15000000
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-41000000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1800000
us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-left:4.533%;text-indent:0;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of financial statements in accordance with GAAP requires management to make estimates and assumptions, based on judgments considered reasonable, which affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting periods. The Company bases its estimates and assumptions on historical experience, known trends and events and various other factors that management believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, the valuation of earn-out shares and revenue recognition. Changes in estimates are recorded in the period in which they become known. Due to the risks and uncertainties involved in the Company’s business and evolving market conditions and, given the subjective element of the estimates and assumptions made, actual results may differ from estimated results.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
CY2023Q3 us-gaap Prepaid Insurance
PrepaidInsurance
706673
CY2022Q4 us-gaap Prepaid Insurance
PrepaidInsurance
913611
CY2023Q3 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
100000
CY2023Q3 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
55953
CY2022Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
72888
CY2023Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
862626
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
986499
CY2023Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
759397
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
753747
CY2023Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
572659
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
496561
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
186738
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
257186
CY2023Q3 us-gaap Depreciation
Depreciation
23000
CY2022Q3 us-gaap Depreciation
Depreciation
24000
us-gaap Depreciation
Depreciation
76000
us-gaap Depreciation
Depreciation
70000
CY2023Q3 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
412005
CY2022Q4 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
767093
CY2023Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
506898
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
282454
CY2023Q3 cmra Accrued Compensation
AccruedCompensation
88189
CY2023Q3 us-gaap Accrued Vacation Current
AccruedVacationCurrent
25972
CY2022Q4 us-gaap Accrued Vacation Current
AccruedVacationCurrent
21194
CY2023Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
193065
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
225023
CY2023Q3 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
1226129
CY2022Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
1295764
CY2023Q3 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
1000000
CY2023Q3 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.0001
CY2023Q3 us-gaap Temporary Equity Accretion Of Dividends
TemporaryEquityAccretionOfDividends
85000
us-gaap Temporary Equity Accretion Of Dividends
TemporaryEquityAccretionOfDividends
258000
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
us-gaap Common Stock Voting Rights
CommonStockVotingRights
one vote
us-gaap Dividends Cash
DividendsCash
0
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4556552
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
1445210
CY2023Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
35756007
CY2023Q3 us-gaap Preferred Stock Convertible Shares Issuable
PreferredStockConvertibleSharesIssuable
930459
CY2023Q3 cmra Common Stock Reserved For Issuance Pursuant To The Arena Purchase Agreement
CommonStockReservedForIssuancePursuantToTheArenaPurchaseAgreement
4204644
CY2023Q3 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
46892872
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4556552
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2152641
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
1.67
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
748000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2481131
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0.56
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
2445
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.59
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
74775
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
0.94
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4556552
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
1.08
CY2023Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P9Y1M6D
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1616053
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
1
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P8Y8M12D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.56
CY2023Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
1900000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y10M24D
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
267560
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
127690
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
847294
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
226985
cmra Class Of Warrant Or Right Issued
ClassOfWarrantOrRightIssued
24714675
cmra Class Of Warrant Or Right Exercised
ClassOfWarrantOrRightExercised
0
cmra Class Of Warrant Or Right Expired
ClassOfWarrantOrRightExpired
0
CY2023Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
35756007
CY2023Q3 cmra Class Of Warrant Or Right Exercisable Shares
ClassOfWarrantOrRightExercisableShares
24758457
CY2022Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
11041332
CY2022Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
11.5
CY2022 cmra Class Of Warrant Or Right Outstanding Weighted Average Remaining Contractual Term
ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualTerm
P4Y4M17D
cmra Class Of Warrant Or Right Issued
ClassOfWarrantOrRightIssued
24714675
cmra Class Of Warrant Or Right Weighted Average Exercise Price
ClassOfWarrantOrRightWeightedAverageExercisePrice
0.73
cmra Class Of Warrant Or Right Issued Weighted Average Remaining Contractual Term
ClassOfWarrantOrRightIssuedWeightedAverageRemainingContractualTerm
P4Y9M7D
CY2023Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
35756007
CY2023Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
4.06
cmra Class Of Warrant Or Right Outstanding Weighted Average Remaining Contractual Term
ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualTerm
P4Y5M1D
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
177463
CY2023Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
5867
CY2023Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
171596
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
171596
CY2023Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
171596
CY2023Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.08
CY2023Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P0Y9M18D
us-gaap Operating Lease Payments
OperatingLeasePayments
163000
us-gaap Operating Lease Payments
OperatingLeasePayments
142000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3150000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3150000
CY2023Q3 cmra Net Loss Attributable To Common Stockholders
NetLossAttributableToCommonStockholders
-2239179
CY2022Q3 cmra Net Loss Attributable To Common Stockholders
NetLossAttributableToCommonStockholders
-3163657
cmra Net Loss Attributable To Common Stockholders
NetLossAttributableToCommonStockholders
-6304799
cmra Net Loss Attributable To Common Stockholders
NetLossAttributableToCommonStockholders
-15329488
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
23113051
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
23113051
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
16024011
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
16024011
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
20448666
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
20448666
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8294938
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8294938
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.1
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.1
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.2
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.2
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.31
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.31
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.85
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.85
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
54386
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
123077
us-gaap Operating Lease Cost
OperatingLeaseCost
167000
us-gaap Operating Lease Cost
OperatingLeaseCost
145000
CY2023Q3 us-gaap Securities Held As Collateral At Fair Value
SecuritiesHeldAsCollateralAtFairValue
50000
CY2022Q4 us-gaap Securities Held As Collateral At Fair Value
SecuritiesHeldAsCollateralAtFairValue
50000
CY2023Q3 cmra Gain Loss On Indemnification Agreement
GainLossOnIndemnificationAgreement
0

Files In Submission

Name View Source Status
cmra-20230930_lab.xml Edgar Link unprocessable
cmra-20230930_def.xml Edgar Link unprocessable
0000950170-23-062130-index-headers.html Edgar Link pending
0000950170-23-062130-index.html Edgar Link pending
0000950170-23-062130.txt Edgar Link pending
0000950170-23-062130-xbrl.zip Edgar Link pending
cmra-20230930.htm Edgar Link pending
cmra-20230930.xsd Edgar Link pending
cmra-ex31_1.htm Edgar Link pending
cmra-ex31_2.htm Edgar Link pending
cmra-ex32_1.htm Edgar Link pending
cmra-ex32_2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
cmra-20230930_cal.xml Edgar Link unprocessable
cmra-20230930_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
cmra-20230930_htm.xml Edgar Link completed
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending